Back to top
more

iRadimed (IRMD)

(Delayed Data from NSDQ)

$69.57 USD

69.57
90,379

-1.12 (-1.58%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $69.50 -0.07 (-0.10%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (158 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Indrajit Bandyopadhyay headshot

3 Medical Instruments Stocks With Potential to Outperform

by Indrajit Bandyopadhyay

Here we discuss ShockWave Medical (SWAV), iRadimed (IRMD) and Tactile Systems Technology (TCMD), which have the potential to outperform their industry going forward.

Zacks Equity Research

IRadimed (IRMD) Q3 Earnings and Revenues Top Estimates

by Zacks Equity Research

iRadimed (IRMD) delivered earnings and revenue surprises of 20.83% and 1.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Inogen (INGN) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Inogen (INGN) delivered earnings and revenue surprises of 56.10% and 8.02%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

IRadimed (IRMD) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

iRadimed (IRMD) delivered earnings and revenue surprises of 12.50% and 0.65%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

After Plunging 27.4% in 4 Weeks, Here's Why the Trend Might Reverse for iRadimed (IRMD)

by Zacks Equity Research

iRadimed (IRMD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Zacks Equity Research

iRadimed (IRMD) is an Incredible Growth Stock: 3 Reasons Why

by Zacks Equity Research

iRadimed (IRMD) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Zacks Equity Research

IRadimed (IRMD) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research

iRadimed (IRMD) delivered earnings and revenue surprises of 4.76% and 0.81%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Is Indivior PLC (INVVY) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Indivior PLC (INVVY) and iRadimed (IRMD) have performed compared to their sector so far this year.

Zacks Equity Research

Here's Why Momentum in iRadimed (IRMD) Should Keep going

by Zacks Equity Research

If you are looking for stocks that are well positioned to maintain their recent uptrend, iRadimed (IRMD) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Zacks Equity Research

Is iRadimed (IRMD) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how iRadimed (IRMD) and Lantheus Holdings (LNTH) have performed compared to their sector so far this year.

Zacks Equity Research

Here's Why Momentum in iRadimed (IRMD) Should Keep going

by Zacks Equity Research

If you are looking for stocks that are well positioned to maintain their recent uptrend, iRadimed (IRMD) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Zacks Equity Research

iRadimed (IRMD) is an Incredible Growth Stock: 3 Reasons Why

by Zacks Equity Research

iRadimed (IRMD) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Zacks Equity Research

Is iRadimed (IRMD) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how iRadimed (IRMD) and AllScripts Healthcare (MDRX) have performed compared to their sector so far this year.

Zacks Equity Research

Recent Price Trend in iRadimed (IRMD) is Your Friend, Here's Why

by Zacks Equity Research

iRadimed (IRMD) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Zacks Equity Research

iRadimed (IRMD) is on the Move, Here's Why the Trend Could be Sustainable

by Zacks Equity Research

If you are looking for stocks that are well positioned to maintain their recent uptrend, iRadimed (IRMD) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Zacks Equity Research

Here's Why "Trend" Investors Would Love Betting on iRadimed (IRMD)

by Zacks Equity Research

If you are looking for stocks that are well positioned to maintain their recent uptrend, iRadimed (IRMD) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Zacks Equity Research

3 Reasons Growth Investors Will Love iRadimed (IRMD)

by Zacks Equity Research

iRadimed (IRMD) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Zacks Equity Research

Here's Why Momentum in iRadimed (IRMD) Should Keep going

by Zacks Equity Research

If you are looking for stocks that are well positioned to maintain their recent uptrend, iRadimed (IRMD) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Zacks Equity Research

3 Reasons Why Growth Investors Shouldn't Overlook iRadimed (IRMD)

by Zacks Equity Research

iRadimed (IRMD) could produce exceptional returns because of its solid growth attributes.

Zacks Equity Research

iRadimed (IRMD) is on the Move, Here's Why the Trend Could be Sustainable

by Zacks Equity Research

iRadimed (IRMD) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Zacks Equity Research

IRadimed (IRMD) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

iRadimed (IRMD) delivered earnings and revenue surprises of 35.29% and 4.94%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

IRadimed (IRMD) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

IRadimed (IRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

IRadimed (IRMD) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

IRadimed (IRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

iRadimed (IRMD) Stock Jumps 11.3%: Will It Continue to Soar?

by Zacks Equity Research

iRadimed (IRMD) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

Here's What Could Help iRadimed (IRMD) Maintain Its Recent Price Strength

by Zacks Equity Research

iRadimed (IRMD) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.